logo

For the Inventor, By the Inventor

Nagano, Japan

Yukiyoshi Ajisawa

This inventor holds 13 USPTO granted patents, plus 1 CIPO patent. Top assignees: Kissei Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kissei Yakuhin Kogyo Kabushiki Kaisha. Active years: 1976-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yukiyoshi Ajisawa. Retrieved from https://idiyas.com/inventor/yukiyoshi-ajisawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 206(Granted Patents)


Location History:

  • Okaya, JA (1976 - 1978)
  • Okaya, JP (1980 - 2001)
  • Nagano, JP (1986 - 2002)

Company Filing History:

goldMedal11 out of 176 
 
Kissei Pharmaceutical Co., Ltd.
 patents
silverMedal3 out of 575 
 
Ono Pharmaceutical Co., Ltd.
 patents
bronzeMedal1 out of 1 
 
Kissei Yakuhin Kogyo Kabushiki Kaisha
 patent
4. 1 out of 1 
 
Kissei Yakuhin Kogyo Kabushiki Kaisha (Kissei Pharmaceutical Co. Ltd.)
 patent
5. 1 out of 1 
 
Nitten Ophthalmic Research Institute Company
 patent
where one patent can have more than one assignee

Years Active: 1976-2002

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 6407139 - Neovascularization inhibitor (2002-06-18),
2. 6376543 - Secondary cataract inhibitor (2002-04-23),
3. 6310086 - Indole derivatives and medicinal compositions containing the same (2001-10-30),
4. 6114383 - Drugs inhibiting progress of pterygium and postoperative recurrence of (2000-09-05),
5. 5356620 - Pharmaceutical compositions containing N-(3,4-dimethoxycinnamoyl) (1994-10-18),
6. 4933354 - 2-pyrrolidone-5-carboxylic acid compounds useful for the treatment of (1990-06-12),
7. 4857524 - Thiazolidine compounds and therapeutic method (1989-08-15),
8. 4632934 - Imidazole derivatives and pharmaceutical use thereof (1986-12-30),
9. 4320134 - Inhibiton of thromboxane synthetase with 1-substituted imidazole (1982-03-16),
10. 4226878 - Imidazole derivative (1980-10-07),
11. 4070484 - Antiallergic composition containing aromatic carboxylic amide (1978-01-24),
12. 4026896 - Aromatic amidocarboxylic acids and pharmaceutical compositions thereof (1977-05-31),
13. 3940422 - Aromatic carboxylic amide derivatives (1976-02-24),

Title: Yukiyoshi Ajisawa: Pioneering Innovator in the World of Technology

Introduction: Yukiyoshi Ajisawa, a visionary inventor hailing from Nagano, Japan, has left an indelible mark on the realm of technology with his unwavering passion for innovation and commitment to excellence. His groundbreaking work continues to serve as an inspiration for aspiring inventors worldwide.

Latest Patents: With an impressive portfolio of 13 patents to his name, Yukiyoshi Ajisawa's latest inventions include a Neovascularization Inhibitor and a Secondary Cataract Inhibitor, both of which showcase his dedication to advancing medical technology and improving patient care.

Career Highlights: Throughout his illustrious career, Yukiyoshi Ajisawa has lent his expertise to renowned companies such as Kissei Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., where he has spearheaded numerous innovative projects that have pushed the boundaries of scientific discovery.

Collaborations: Collaborating closely with esteemed colleagues such as Kinji Iizuka and Yukihiko Kinoshita, Yukiyoshi Ajisawa has fostered a culture of creativity and collaboration, leading to the development of groundbreaking technologies that have revolutionized the industry.

Conclusion: Yukiyoshi Ajisawa's legacy as a pioneering inventor and his tireless pursuit of excellence serve as a testament to the transformative power of innovation. His contributions to the world of technology will undoubtedly continue to shape the future of invention for generations to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…